Log inTry free

Attovia Therapeutics (ATTO) stock

Market cap $812M

$17.50
-2.75%

Market closed. Prices as of Tuesday's close.

Quality Score
1
Below Average
In its industry
#113of 308
Biotech

New listing, trading since Aug 5, 2026. 44 trading days so far, so 5 of the 14 checks wait for more history.

NextQ4 2026“…concept in chronic pruritus and high-itch atopic dermatitis (AD); complete Phase 1b data expected in Q4 2026”Trial data · 8-K, Sep 2

Follow ATTO's trial news. Pro members can get an alert when Attovia Therapeutics files news, and see its trials, share raises, and its CEO's filings.

Get an optional alert when ATTO files news on its trialsSee it live, free until tomorrow morning. No account. No card. Then keep going with a free account.

We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.

Holding it back

Moves 11.1% a day with no profit behind it.

1 more reason behind ATTO's 1, for Pro members

What's next for ATTO, and how long its cash lasts

From Attovia Therapeutics’s SEC filings and ClinicalTrials.gov: the company’s own words, the registry’s dates, and arithmetic, not a forecast. Companies often miss their own dates.

Next step the company has named

Q4 2026“ATTO-1310 demonstrated preliminary clinical proof of concept in chronic pruritus and high-itch atopic dermatitis (AD); complete Phase 1b data expected in Q4 2026”Trial data · 8-K, Sep 2

What it means: the first look at a trial’s main results, as the company reports them.

Lead program
ATTO-1310 · Chronic Pruritus of Unknown Origin · Phase 2
Its trial
Efficacy and Safety of ATTO-1310 in the Treatment of Participants With Chronic Pruritus of Unknown OriginPhase 2 · Not yet recruiting · 300 people · main data estimated Aug 30, 2028 · NCT07833306

1 more trial, 1 more milestone and 2 filings, for Pro members.

Cash runway Jun 30 balance sheet

$115M in cash

Fewer than four quarters of cash flow are on file.

What it means: a runway is counted only when each of the last four quarters used cash. The company's own estimate is “into 2030” (8-K, Sep 2). It has raised money since that balance sheet, which is not counted here.

For Pro members: the cash used each quarter, and the math.

Dilution on the horizon

No shelf registration of its own or at-the-market program on file in the last three years.

A shelf lets a company sell shares later; an at-the-market program sells them into the market over time. Neither is a sale by itself.

For Pro members: 1 raise and its amount, and the share count against a year ago.

Insiders

Director Colin Walsh bought 585,000 shares on Aug 6. 1 more insider trade this year.

From their own Form 4 filings: buys and sales in the market, not awards or shares withheld for tax.

For Pro members: every trade.

Get an optional alert when ATTO files news on its trialsSee it live, free until tomorrow morning. No account. No card. Then keep going with a free account.

See every upcoming FDA date →

FDA dates in the next 60 days

Decision dates and advisory committee meetings the companies have announced in their own filings, soonest first and small companies first.

DateStockDrug

8 more FDA dates and 112 trial data dates in the next 60 days. Pro members see every one, with the cash against its date and an optional alert before it. Get in free →

Why ATTO scores 1

Below AverageTransition, 2 of 14 checks firingWhat the Quality Score means

Poor is below 0. Average starts at 6, Above Average at 11, Excellent at 15, and Exceptional at 20.

  • +2Chart checks 2 of 14 firing right now, one point each
  • −2Volatility moves 11.1% a day with no profit or positive free cash flow over four quarters on fileA daily range of 5% or more with nothing behind it (no profit or cash flow, sales shrinking, or 10% more shares outstanding with no free cash flow): -1, or -2 from 8%.
  • Insider trades adds

No effect today: Long-term trend, Run-up, Size, Profit, Growth, Dilution, Cash flow, Persistence, and News.

What every line is worth, and the reason behind it, on ATTO and every other stock.Get in free →

Price, score, chart checks, and the industry rank are from a snapshot taken at 12:33 AM ET, at least 15 minutes behind. How we rank stocks.

What's next

Expected to report Wed Nov 11, after the close

After its last report it closed +4.6%.

Thu Aug 5: One year since its IPOListed Aug 5, 2026 at $17.

What would turn ATTO's score around: 3 things, for Pro members

Alert me when ATTO's Quality Score turns up

See it live, free until tomorrow morning. No account. No card. Then keep going with a free account.

Here is what Pro members see.

  • The same page for Pro members, on AMD

    Its Quality Score and rank, the line that drives it, and the live price with the bid and ask.

  • The full chart

    A year of candles to start, out to the whole history, with insider trades marked and the Quality Score under the price.

  • Every line of the score

    Price action, the company, and signals, each with its points, on ATTO and every other stock.

  • FDA dates, counted down

    Each date in the company's own words, its cash against the date, and an optional alert before it.

  • Why a stock ranks

    Its Quality Score, its rank, and the reasons behind it, on one card.

  • CEOs buying their own stock

    Every CEO buy, biggest names first. Sort, filter, download a CSV, and set optional alerts.

  • Congress trades

    Each member's trades. Sort, filter, download a CSV, and set optional alerts.

  • All 14 chart checks

    Trend, volume, tight range, and buying, each lit when it fires, its rule a tap away.

  • Earnings, week by week

    Who reports each day, and how each stock took its last four reports. Optional alerts before them.

  • The market map

    Every stock a box, colored by its Quality Score.

  • Themes, ranked live

    AI chips, quantum, nuclear, defense, space, and more, each stock ranked by its Quality Score.

  • The top 10, every day

    The ten highest Quality Scores at each close, kept day by day, week by week.

  • Optional alerts, your way

    Pick a stock, a score, a price, a filing, or a whole scan. It tells you by push, email, or the bell.

  • Your watchlist, scored

    Your stocks by Quality Score, today's move, or name, with optional alerts.

  • A trade plan, from the chart

    Entry, stop, and two targets on every stock's page. Type your risk and it sizes the trade.

  • On your phone and your laptop

    The same account and watchlist on both, each laid out for its screen.

  • Prices refresh every 2.5 seconds during market hours.
  • Optional alerts by push, email, or the bell.
  • Add it to your Home Screen and it opens like an app.

ATTO has 2 of 14 checks firing

One per group is shown here.

Trend1 of 5 shown
MA FAN21 EMAW.EMAHH/HL52W HI

Averages stacked in order, price near its high.

Volume1 of 3 shown
VOLVDUU/D VOL

Heavy volume on the run, quiet volume at rest.

Tight range1 of 3 shown
ATR SQZSQUEEZENR7

The daily range is tight against its own recent history.

Buying1 of 3 shown
OBV+CLOSE HISPRING

Closes near the high, and buyers step in on dips.

The other 10 checks on ATTO, and all 14 on every stock.Get in free →

Also on the chart

Not scored

Shown for reference. None of these counts toward the Quality Score: in our tests on 20 years of daily prices, none of them improved it.

How ATTO ranks in Biotech

ATTO is #113 of 308 by Quality Score. The top three are shown with their scores, and more by name.

More in Biotech, on the Healthcare page

When does ATTO report earnings, and what happens after?

Expected to report Wed Nov 11, after the close (in 35 days). Not yet confirmed by the company.

ReportedGapReaction5 sessions
Sep 2, 2026After close+1.4%+4.6%-2.6%

The gap is the next open against the close before the report; the reaction is where that session closed. ATTO closed higher after 1 of its last 1. Past behavior, not a forecast.

Report dates and past reactions come from sessions that have already closed, so none of these figures move.

Who is trading ATTO

ATTO insider trades

6 insiders bought $52.4M across 9 filings, and 2 insiders sold $4.5M across 44 filings, in the last 6 months. The newest:

BuyGoldman Sachs Group Inc$8.5MInsiderat $17.00 on Aug 6, filed Aug 13
All 53 insider filings on ATTO from the last six months, for Pro members.Get in free →

An insider has two business days to file a Form 4, so the trade is already days old when it becomes public. Shown as filed, with no delay.

ATTO's officers and directors

Officers and directors with a Form 4 here in the last 3 months. Open one for their trades at every company.

See insider trades by person

About Attovia Therapeutics

Attovia Therapeutics Inc is a clinical stage biotechnology company focused on research and development of therapeutic products in the fields of immune-mediated diseases. Its product pipeline includes ATTO-1310 and ATTO-2306 for immune-dermatology indications and ATTO-1091 for inflammatory diseases, including inflammatory bowel disease (IBD). The company's product candidates are developed using its ATTOBODY biologics platform.

San Carlos, CAattovia.com

Pro members see every line of every stock's score.

  • Real-⁠time prices, no delay
  • Every line of ATTO's score, with the points and the reason
  • All 14 checks on ATTO and on all 3,283 stocks
  • Every stock ranked, with the chart
  • Every filing, and optional alerts on ATTO
BreakawayAug 13Goldman Sachs Group Inc bought ATTO$8.5M at $17.00, filed Aug 13

What a filing on ATTO would have sent. Alerts are optional.

See all 14 checks on ATTOSee it live, free until tomorrow morning. No account. No card. Then keep going with a free account.

Straight Answers

Are the prices delayed?

Only on the public pages, which run at least 15 minutes behind. Pro members, and anyone on a guest pass, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.

Where does the data come from?

Daily bars, quotes, reference data, headlines, and short interest come from Massive, formerly Polygon, a licensed market data vendor. The age of the quotes is shown at the top of every page. Insider trades, notable holders and profits come straight from the SEC. That means Form 4 filings, 13F filings and XBRL financial data on EDGAR. Government filings come from the public STOCK Act and Office of Government Ethics disclosures. The market-wide headlines on the market line also come from the public headline feeds CNBC, MarketWatch and Yahoo Finance publish, shown as the headline, the source and a link to the article. Splits, dividends, and the financial statements on each ticker page come from the vendor's reference data. The 8-K filings on EDGAR are read for the items that move a price. Five years of history is loaded for every stock. So the 200-day and 52-week checks rest on real history. Options flow is not part of the product.

Do I need an account?

Not to start. Tap any green button and you're in, free, with no email and no password. To keep going, create a free account with Google, Apple, or your email. There is no password to make up.

Is this investment advice?

No. It is a screening tool that scores stocks on the chart, the company's own results, and the news and filings. It does not know your situation and it is not a recommendation to buy or sell anything. Please do your own research.

The price, the score, the chart checks and readings, and the industry rank on this page are delayed at least 15 minutes. Filings are shown as filed, because a disclosure is already days or weeks old when it becomes public. Earnings dates and past reactions are settled sessions.